Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation
Shots:
- Health Canada approved Galderma’s Restylane SHAYPE, a hyaluronic acid injectable designed for the temporary augmentation of the chin by building and shaping the bone with deep injection for a bone-mimicking effect
- As per the 12mos. study conducted across 9 sites in Canada, 91% of patients reported improvement at 12mos. post being treated with Restylane SHAYPE whereas 95% reported natural results & 84% agreed to be retreated with Restylane SHAYPE
- Restylane is a hyaluronic acid filler produced by using the company’s NASHA HD technology. The company expects to market Restylane SHAYPE in Canada from Feb 2024 & file for regulatory approval in other countries
Ref: Galderma | Image: Galderma
Related News:- Galderma Reports Results from the P-III (READY-3) Study of RelabotulinumtoxinA for Treating Frown Lines and Crow’s Feet
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
